Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Counts Board Vote Win As Peltz Claims 'Change' Message Delivered

Executive Summary

Procter & Gamble says preliminary results keep billionaire activist investor Nelson Peltz off its board and re-elect its 11 incumbents. However, Peltz plans to challenge the vote outcome and analysts agree that his pressure for change at P&G scored points with shareholders.

You may also be interested in...



NDI Notification Costs Estimate, P&G Board: Health And Wellness Industry News

FDA NDI notification costs estimate unchanged; P&G proxy vote update favors Peltz; and trio of advertising violations for California supplement, skin care firms.

P&G Board Seat Swings To Peltz In Ongoing Vote Tally

P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.

P&G Board Seat Swings To Peltz In Ongoing Vote Tally

P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel